За 10 лет, прошедшие с момента создания концепции ХБП, во всем мире накоплен огромный объем данных, показывающих высокую распространенность заболеваний почек и большой социально-экономический ущерб, связанный с развитием терминальной почечной недостаточности. Не вызывает сомнения, что важная задача предупреждения дальнейшего прироста больных с почечной недостаточностью, снижения расходов на высокозатратную заместительную почечную терапию и уменьшения сердечно-сосудистого риска в популяции, обусловленного почечной дисфункцией, выходит за рамки одной медицинской специальности. Концепция ХБП создает универсальную платформу для широкого и эффективного взаимодействия всего медицинского сообщества с целью профилактики, раннего выявления и торможения прогрессирования хронических заболеваний почек разной этиологии, без чего сегодня невозможна реализация масштабных задач отечественного здравоохранения по сбережению работоспособного населения и оздоровлению нации.

 

Представленные рекомендации не только обобщают принятые в мире подходы к решению данной проблемы, но и используют результаты отечественных исследований и накопленный на сегодняшний день опыт адаптации иностранных и международных рекомендаций по ХБП к российским условиям. Очевидно, что дальнейшие перспективы внедрения концепции ХБП в практику отечественного здравоохранение связаны не только с совершенствованием основных ее положений, но и с разработкой более детальных рекомендаций по отдельным направлениям ведения больных с дисфункцией почек.

 

 

1. Бикбов БТ, Томилина НА. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998–2007 гг. (Аналитический отчет по данным Российского регистра заместительной почечной терапии). Нефрология и диализ 2009; 11 (3): 144-233

2. Дедов ИИ, Шестакова МВ, ред. Алгоритмы специализированной медицинской помощи больным с сахарным диабетом. Издание второе. М., 2006

3. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза (IV пересмотр). Российские рекомендации. М., 2009

4. Добронравов ВА. Эпидемиология диабетической нефропатии: общие и региональные проблемы. Нефрология 2002; 6(1):16-22

5. Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза. Роль фактора роста фибробластов 23 и klotho. Нефрология 2011; 15(4): 11-20

6. Добронравов ВА, Смирнов АВ, Драгунов СВ и др. Эпидемиология хронической болезни почек в Вологодской области. Нефрология 2004; 8(1): 36-41

7. Добронравов ВА, Смирнов АВ, Драгунов СВ и др. Эпидемиология хронической почечной недостаточности в СевероЗападном регионе России: на пути к созданию регистра хронической почечной болезни. Тер арх 2004; 76(9): 57-61

8. Есаян АМ. Тканевая ренин-ангиотензиновая система почки. Новая стратегия нефропротекции. Нефрология 2008; 6(3): 8-16

9. Каюков ИГ, Смирнов АВ, Добронравов ВА. Рентгеноконтрастная нефропатия. Нефрология 2007; 11(3): 93-101

10. Кучер АГ, Каюков ИГ, Есаян АМ, Ермаков ЮА. Влияние количества и качества белка в рационе на деятельность почек. Нефрология 2004; 8(2): 14-34

11. Кучер АГ, Каюков ИГ, Григорьева НД, Васильев АН. Лечебное питание на различных стадиях хронической болезни почек. Нефрология и диализ 2007; 9(2):118-136

12. Мухин НА, Балкаров ИМ, Моисеев ВС и др. Хронические прогрессирующие нефропатии и образ жизни современного человека. Тер арх 2004; 76(9): 5-10 

13. Мухин НА, Моисеев ВС, Кобалава ЖД и др. Кардиоренальные взаимодействия: клиническое значение и роль в патогенезе заболеваний сердечно-сосудистой системы и почек. Тер арх 2004; (6):39-46

14. Национальные рекомендации по профилактике, диагностике и лечению артериальной гипертонии. М., 2008

15. Нефрология. Национальное руководство. Под ред. НА Мухина. ГЭОТАР-Медиа, М., 2009, 720 с

16. Практические рекомендации KDIGO по диагностие, профилактике и лечению минеральных и костных нарушений при хронической болезни почек (ХБП-МКН). Краткое изложение рекомендаций. Нефрология 2011; 15(1): 88-95 

17. Смирнов АВ, Есаян АМ, Каюков ИГ. Хроническая болезнь почек: на пути к единству представлений. Нефрология 2002; 6(4): 11-17

18. Смирнов АВ. Дислипопротеидемии и проблемы нефропротекции. Нефрология 2002; 6(2): 8-14

19. Смирнов АВ, Каюков ИГ, Есаян АМ и др. Превентивный подход в современной нефрологии. Нефрология 2004;. 8(3): 7-14 

20. Смирнов АВ, Добронравов ВА, Бодур-Ооржак АШ и др. Эпидемиология и факторы риска хронических болезней почек: региональный уровень общей проблемы. Тер арх 2005; (6): 20-27

21. Смирнов АВ, Добронравов ВА, Бодур-Ооржак АШ и др. Распространенность и заболеваемость поздними стадиями хронической болезни почек в Республике Тыва. Нефрология 2005; 9(4): 25-29

22. Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардиоренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005;9(3): 7-15

23. Смирнов АВ, Каюков ИГ, Есаян АМ и др. Проблема оценки скорости клубочковой фильтрации в современной нефрологии: новый индикатор – цистатин С. Нефрология 2005; 9(3): 16-27

24. Смирнов АВ, Добронравов ВА, Каюков ИГ и др. Эпидемиология и социально-экономические аспекты хронической болезни почек. Нефрология 2006; 10(1): 7-13

25. Смирнов АВ, Седов ВМ, Лхаахуу Од-Эрдэнэ, Каюков ИГ и др. Снижение скорости клубочковой фильтрации как независимый фактор риска сердечно-сосудистой болезни. Нефрология 2006; 10(4): 7-17

26. Смирнов АВ, Добронравов ВА, Каюков ИГ и др. Рекомендации Научно-исследовательского института нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И.П. Павлова: определение, классификация, диагностика и основные направления профилактики хронической болезни почек у взрослых. Левша, СПб, 2008; 51

27. Смирнов АВ, Добронравов ВА, Каюков ИГ. Проблема модификации классификации хронической болезни почек. Нефрология 2010; 15(2): 7-15

28. Смирнов АВ, Кучер АГ, Каюков ИГ, Есаян АМ. Руководство по лечебному питанию для больных хронической болезнью почек. Триада, СПб.-Тверь, 2009; 240

29. Шилов Е.М. Хроническая болезнь почек и программа народосбережения России. Саратов, 2011

30. Швецов МЮ, Бобкова ИН, Колина ИБ, Камышова ЕС. Современные принципы диагностики и лечения хронической болезни почек: методическое руководство для врачей. Шилов ЕМ, ред. Саратов, 2011

31. Шутов АМ, Саенко ЮВ. Плеотропные кардиопротективные эффекты эритропоэтина. Нефрология 2006; 10(4): 18-22 

32. Рerthoux F, Jones E, Gellert R et al. Epidemiological data of treated end-stage renal failure in the European Union (EU) during the year 1995; Report of European Renal Association Registry and the National Registries. Nephrol Dial Transplant 1999; 14: 2332-2342

33. Bommer J. Prevalence and socio-economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002;. 17[Suppl]: 11; 8-12

34. Brantsma AH, Bakker SJ, Hillege HL et al. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005; 28(10): 2525-2530

35. Burnier M, Phan O, Wang Q. High salt intake: a cause of blood pressure-independent left ventricular hypertrophy? Nephrol Dial Transplant 2007;22(9):2426-2429 

36. Casas JP, Chua W, Loukogeorgakis S et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005;366 (9502): 2026-2233 

37. Chauveau P, Couzi L, Vendrely B et al. Long-term outcome on renal replacement therapy in patients who previously received a keto acid-supplemented very-low-protein diet. Am J Clin Nutr 2009;90(4):969-974

38. Chen J, Munter P, Hamm LZ et al. The metabolic syndrome and chronic kidney disease in US adults. Ann Intern Med 2004; 140: 167-174

39. Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-2572 

40. Cockcroft DW, Gault MH. Prediction of creatinine from serum creatinine. Nephron 1976;16(1): 31-41

41. Delanaye P, Cavalier E, Mariat C et al. MDRD or CKDEPI study equations for estimating prevalence of stage 3 CKD in epidemiological studies: which difference? Is this difference relevant? BMC Nephrol 2010;11: 8. Published online 2010 June 1. doi: 10.1186/1471-2369-11-8]

42. de Portu S, Citarella A, Cammarota S, Menditto E, Mantovani LG. Pharmaco-Economic Consequences of Losartan Therapy in Patients Undergoing Diabetic End Stage Renal Disease in EU and USA. Clin Exp Hypertens 2011;33(3):174-178

43. Drueke TB, Locatelli F, Clyne N et al. CREATE Investigators. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355(20): 2071-2084 

44. European Best Practice Guidelines, Expert Group on Hemodialysis, European Renal Association. Section I. Measurement of renal function, when to refer and when to start dialysis. Nephrol Dial Transplant 2002; 17 [suppl 7]; 7-15 

45. Foley RN, Wang C, Snyder JJ, Collins AJ. Cystatin C levels in U.S. adults, 1988-1994 versus 1999-2002: NHANES. Clin J Am Soc Nephrol 2009; 4(5):965-972 

46. Forman JP, Brenner BM. «Hypertension» and «microalbuminuria»: The bell tolls for thee. Kidney Int 2006; 69: 22-28

47. Fouque D, Laville M. Low protein diets for chronic kidney disease in non diabetic adults. Cochrane Database Syst Rev 2009; 8;(3): CD001892 

48. Fouque D, Pelletier S, Mafra D, Chauveau P. Nutrition and chronic kidney disease. Kidney Int 2011; 80(4):348-357

49. Fried ZF, Orchard TJ, Kasiske BZ. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001; 59: 260- 269

50. roissart M, Rossert J, Jacquot C, Paillard M, Houillier P. Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol 2005;16(3):763-773 

51. Glynn LG, Reddan D, Newell J et al. Chronic kidney disease and mortality and morbidity among patients with established cardiovascular disease: a West of Ireland community-based cohort study. Nephrol Dial Transplant 2007; 22(9):2586-2594

52. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13):1296-305

53. Goodman WG, London G, Amann K et al. Vascular calcification in chronic kidney disease. Am J Kidney Dis 2004;43(3): 572-579

54. Hallan S, Asberg A, Lindberg M, Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J Kidney Dis 2004; 44(1): 84-93

55. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002; 62(1): 220-228 

56. Haroun NK, Jaar BG, Hoffman SC et al. Risk factors for chronic Kidney disease: a prospective study of 23.534 men and women in Washington Country, Maryland. J Am Soc Nephrol 2003; 14: 2934-2941

57. He J, Whelton PK. Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials. Am Heart J 1999; 138(3 Pt 2): 211-219

58. Henry RM, Kostense PJ, Bos G et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62: 1402-1407

59. Hsu C-Y, Lin F, Vittinghoff E, Shlipac MG. Racial differences in the progression from chronic renal insufficiency to end-stage renal disease in the United State. J Am Soc Nephrol 2003; 14: 2902-2907

60. Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS. Body mass index and risk for end-stage renal disease. Ann Intern Med 2006 3;144(1):21-28

61. Ibrahim S, Rashid L, Darai M. Modification of diet in renal disease equation underestimates glomerular filtration rate in egyptian kidney donors. Exp Clin Transplant 2008;6(2):144-148 

62. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352(9131):837-853 

63. Jafar TH, Stark PC, Schmid CH et al. AIPRD Study Group. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003; 139(4): 244-252

64. Joint Speciality Committee on Renal Medicine of the Royal College of Physicians and the Renal Association atRCoGP. Chronic Kidney Disease in adults: UK guidelines for management and referral. Royal College of Physicians, London: 2006

65. Kidney Disease Outcome Quality Initiative. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43: S1-S290 

66. Klahr S, Levey AS, Beck GJ et al.The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994;330(13):877-884

67. Klausen KP Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46(1):33-37

68. Kopple JD, Feroze U. The effect of obesity on chronic kidney disease. J Ren Nutr 2011; 1(1):66-71

69. Krikken JA, Lely AT, Bakker SJ, Navis G. The effect of a shift in sodium intake on renal hemodynamics is determined by body mass index in healthy young men. Kidney Int 2007; 71(3):260-265

70. Lentine K, Wrone EM. New insights into protein intake and progression of renal disease. Curr Opin Nephrol Hypertens 2004; 13(3):333-336 

71. Levey AS, Bosch JP, Lewis JB. A more accurate method to estimate glomerular filtration rate from serum creatinine; a new prediction equation. Ann Intern Med 1999;130(8): 461-470

72. Levey AS, Greene T, Kusek JW, Beck GJ. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000; 11: A0828

73. Levey AS, Eckardt KU, Tsukamoto Y et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67(6): 2089-20100

74. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150: 604–612

75. Levey AS, de Jong PE, Coresh J et al. The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2010; http:/www.kidney-international.org

76. Locatelli F, Aljama P, Canaud B et al. Anaemia Working Group of European Renal Best Practice (ERBP). Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study. Nephrol Dial Transplant 2010; 25(9): 2846-2850

77. Locatelli F, Covic A, Eckardt KU et al. ERA–EDTA ERBP Advisory Board. Anaemia management in patients with chronic idney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant 2009; 24:348-354

78. Locatelli F, Pozzoni P, Del Vecchio L. Epidemiology of chronic kidney disease in Italy: Possible therapeutical approaches. J Nephrol 2003; 16: 1-10

79. Lopez-Novoa JM, Rodriguez-Pena AB, Ortiz A et al. Etiopathology of chronic tubular, glomerular and renovascular nephropathies: clinical implications. J Transl Med 2011; 9:13. Published online 2011 Jan 20. doi: 10.1186/1479-5876-9-13

80. Ma YC, Zuo L, Chen JH et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006;17(10): 2937-2944

81. Maki DD, Ma JZ, Louis TA, Kasiske BL.Long-term effects of antihypertensive agents on proteinuria and renal function. Arch Intern Med 1995;155(10):1073-1080 

82. MacKinnon M, Shurraw S, Akbari A et al. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48(1): 8-12

83. Mann JFE. Cardiovascular risk in patients with mild renal insufficiency: implication for the use of ACE inhibitors. La Presse Medicale 2005; 34(18): 1303-1308

84. Mann JF, Schmieder RE, McQueen M et al. The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET®) Investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET® study): a multicentre, randomised, double-blind, controlled trial. Lancet. 2008;372:547–553

85. Matsuo S, Imai E, Horio M et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53(6):982-992

86. McClellan WM, Flanders WD. Risk factors for progressive chronic kidney disease. J Am Soc Nephrol 2003; 14: S65-S70

87. Meloni C, Morosetti M, Suraci C et al. Severe dietary protein restriction in overt diabetic nephropathy: benefits or risks? J Ren Nutr 2002;12(2): 96-101 

88. Meloni C, Tatangelo P, Cipriani S, Rossi V, Suraci C, Tozzo C, Rossini B, Cecilia A, Di Franco D, Straccialano E, Casciani CU. Adequate protein dietary restriction in diabetic and nondiabetic patients with chronic renal failure. J Ren Nutr 2004; 14(4):208-213

89. Mitch WE. Dietary therapy in CKD patients – the current status. Am J Nephrol 2005; 25[suppl.1]: 7-8 

90. Muntner P, He J, Astor BC et al. Traditional and nontraditional risk factors predict coronary heart disease in 

chronic kidney disease: results from the Atherosclerosis Risk in Communities Study. J Am Soc Nephrol 2005; 16:529-538

91. Majunath G, Tighionart H, Ibrahim H et al. Level of kidney function as a risk factors for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47-55

92. Macdougall IC, Temple RM, Kwan JT. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 2007 22(3):784-793 

93. Muntner P, Coresh J, Smith JC et al. Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000; 58: 293-301

94. National Kidney Foundation KD: Clinical practice guidelines for chronic Kidney disease: Evaluation, classification and stratification. Am J Kidney Dis 2002;39 [Suppl 1]: S1-S266 

95. Nitsch D, Dietrich DF, von Eckardstein A et al. Prevalence of renal impairment and its association with cardiovascular risk factors in a general population: results of the Swiss SAPALDIA study. Nephrol Dial Transplant 2006; 21(4): 935-944

96. Ohkubo Y, Kishikawa H, Araki E et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28(2): 103-117

97. Pecoits-Filho R. Dietary protein intake and kidney disease in Western diet. Contrib Nephrol 2007;155:102-112 

98. Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995 15; 123(10):754-762 

99. Pijls LT, de Vries H, van Eijk JT, Donker AJ. Protein restriction, glomerular filtration rate and albuminuria in patients with type 2 diabetes mellitus: a randomized trial. Eur J Clin Nutr 2002; 56(12):1200-1207

100. Pinto-Siersma SJ, Mulder J, Janssen WM et al. Smoking is related to albuminuria and abnormal renal function in nondiabetic persons. Ann Intern Med 2000; 133:585- 591 

101. Prakash S, Pande DP, Sharma S et al. Randomized, double-blind, placebo-controlled trial to evaluate efficacy of ketodiet in predialytic chronic renal failure. Ren Nut 2004; 14(2):89-96 

102. Remuzzi G, Ruggenenti P, Perna A et al. RENAAL Study Group Continuum of renoprotection with losartan at all stages of type 2 diabetic nephropathy: a post hoc analysis of the RENAAL trial results. J Am Soc Nephrol 2004; 15(12): 3117-3125 

103. Riccioni G. Aliskiren in the treatment of hypertension and organ damage. Cardiovasc Ther 2011; 29(1):77-87

104. Ritz E. Hypertension and kidney disease. Clin Nephrol 2010;74 [Suppl 1]: S39-43

105. Ritz E. Salt-friend or foe? Nephrol Dial Transplant 2006 21(8):2052-2056

106. Ritz E, Dikow R, Morath C, Schwenger V. Salt-a potential‚ uremic toxin‘? Blood Purif 2006;24(1):63-66

107. Rodger RSC, Williams B. Consensus conference on early chronic kidney disease. Foreword. Nephrol Dial Transplant 2007; 22 [suppl 9]: ix:1 

108. Rodrigo E и соавт. Measurement of renal function in preESRD patients. Kidney Int 2002; 61[Suppl 80]: S11-S17]

109. Rule AD, Larson TS, Bergstralh EJ et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004;141: 929–937

110. Rutkowski B. Changing pattern of end-stage renal failure in Central and Eastern Europe. Nephrol Dial Transplant 2002; 15: 156-160

111. Sacks FM, Lichtenstein A, Van Horn L, Harris W, KrisEtherton P, Winston M. Soy protein, isoflavones, and cardiovascular health: a summary of a statement for professionals from the american heart association nutrition committee. Arterioscler Thromb Vasc Biol 2006;26(8):1689-1692

112. Saito A, Kaseda R, Hosojima M, Sato H. Proximal tubule cell hypothesis for cardiorenal syndrome in diabetes. Int J Nephrol 2010 Dec 9;2011:957164

113. Schaeffner ES, Kurth T, Curhan GC et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 2003; 14: 2084- 2091 

114. Schmieder RE Schrader J, Zidek W et al. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007; 96(5):247-257

115. Schiepati A, Remuzzi G. Chronic renal disease as a public health problem: Epidemiology, social and economic implications. Kidney Int 2005; 68[Suppl 98]: S7-S10

116. Segura J, Campo C, Ruilope LM. Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. Kidney Int 2004; [Suppl 92]:S45-S49

117. Silverberg DS, Wexler D, Iaina A.The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron? J Nephrol 2004;17(6):749-761

118. Singh AK, Szczech L, Tang KL et al. CHOIR Investigators. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355(20):2085-2098 

119. Strippoli GF, Navaneethan SD, Johnson DW et al. Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials. BMJ 2008; 336(7645):645-651 

120. Teschan PE, Beck GJ, Dwyer JT et al. Effect of a ketoacidaminoacid-supplemented very low protein diet on the progression of advanced renal disease: a reanalysis of the MDRD feasibility study. Clin Nephrol 1998 50(5):273-283

121. Tanaka H, Shiohira Y, Uezu Y et al. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69(2):369-374

122. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329(14):977-986

123. U.S. Renal Data System. USRDR 2004 Annual Data Report, Bethesda, MD, National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2004

124. Uribarri J, Tuttle KR. Advanced glycation end products and nephrotoxicity of high-protein diets. Clin J Am Soc Nephrol 2006 1(6):1293-1299

125. Vanholder R и соавт. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 2005;20(6):1048-1056

126. Warmoth L, Regalado MM, Simoni J et al. Cigarette smoking enhances increased urine albumin excretion as a risk factor for glomerular filtration rate decline in primary hypertension. Am J Med Sci 2005; 330(3): 111-119

127. Weiner DE, Tighiouart H, Levey AS et al. Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. J Am Soc Nephrol 2007;18 (3):960-966

128. Wesson DE, Nathan T, Rose T, Simoni J, Tran RM. Dietary protein induces endothelin-mediated kidney injury through enhanced intrinsic acid production. Kidney Int 2007 71(3):210-221

129. Williams B, Poulter NR, Brown MJ et al. British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18(3): 139-185

130. Xue JL, Ma JZ, Louis TA, Collins AJ. Forecast of the number of patients with end-stage renal disease in the United States to the year 2010. J Am Soc Nephrol 2001; 12: 2753-2758